CD274 and triple-negative breast carcinoma: JBCS guideline recommends atezolizumab in combination with nab-paclitaxel, nanoparticle albumin–bound paclitaxel, as a highly preferred treatment against locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.